LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) presented preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients demonstrated a 40% disease control rate with encouraging survival trends and an acceptable safety profile, supporting continued enrollment in an expanded cohort.
The company is investigating the combination's potential to enhance immunotherapy response in ovarian clear cell carcinoma, a challenging cancer subtype. LB-100 is LIXTE's lead compound and first-in-class clinical PP2A inhibitor, which has shown to be well-tolerated in cancer patients at doses associated with anti-cancer activity. According to published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, potentially improving outcomes for cancer patients.
This development represents part of a pioneering effort in an entirely new field of cancer biology called activation lethality, advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. Additional information about the company's research can be found at https://www.lixte.com.
Through its wholly owned subsidiary Liora Technologies Europe Ltd., LIXTE is also pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora's proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. More details about this technology are available at https://www.lioratechnologies.com.
The interim results suggest that LB-100 in combination with immunotherapy could address significant unmet needs in ovarian cancer treatment, particularly for clear cell carcinoma which often shows limited response to conventional therapies. For business and technology leaders, this development highlights how targeted pharmaceutical approaches combined with immunotherapy represent the next frontier in oncology treatment, potentially creating new market opportunities while addressing critical healthcare challenges. The continued enrollment in expanded cohorts indicates confidence in both the safety profile and therapeutic potential of this combination approach.
